Visiogene — ocular gene and protein therapeutics
Blue, teal and lime iris concept illustration

Visiogene / Ocular therapeutics

Ocular therapeutics.
Advancing toward
the clinic.

Visiogene is a biotechnology company approaching IND-enabling development. We combine gene and protein delivery with therapies targeting fibrosis, neovascularization and complement-mediated retinal injury.

Explore the science

The portfolio

Therapeutic programs. Enabling platforms.

Distinct therapeutic programs.
Connected by delivery and ocular biology.

01Therapeutic program

Wet AMD

Decorin gene therapy targeting subretinal fibrosis and pathological neovascularization.

View program
02Therapeutic program

Glaucoma

Gene therapy targeting trabecular meshwork fibrosis and elevated intraocular pressure.

View program
03Delivery technology

Retinal-penetrating AAV

AAV-IKV: gene delivery to photoreceptors and RPE from the vitreous.

View platform
04Delivery technology

Nuc1 platform

Functional protein delivery into retinal cells without cargo conjugation.

View platform
05Therapeutic program

Complement therapies

Enhanced sCD59 therapy with upstream complement regulation, including C3.

View program

Strategic partnerships

Start with the science.

Technology collaborations, strategic partnerships and investment discussions.

Contact Visiogene